LEADER 01353nam  2200373Ia 450 
001 9910699352803321
005 20230902161950.0
035   $a(CKB)5470000002402388
035   $a(OCoLC)502243286
035   $a(EXLCZ)995470000002402388
100   $a20100128d1999      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $equalifying for pediatric exclusivity under section 505A of the Federal Food, Drug, and Cosmetic Act
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research :$cCenter for Biologics Evaluation and Research,$d[1999]
215   $a1 online resource (ii, 22 pages)
300   $a"Procedural."
300   $a"Revised, September 1999."
517   $aGuidance for industry 
606   $aPediatrics$zUnited States
606   $aDrug approval$zUnited States
615  0$aPediatrics
615  0$aDrug approval
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910699352803321
996   $aGuidance for industry$93434577
997   $aUNINA